跳转至内容
Merck
CN

760404

乙醇钽(V)

packaged for use in deposition systems

别名:

PET, Pentaethoxytantalum, Pentaethyl tantalate, Tantalum pentaethoxide

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

线性分子式:
Ta(OC2H5)5
化学文摘社编号:
分子量:
406.25
UNSPSC Code:
12352103
NACRES:
NA.23
PubChem Substance ID:
EC Number:
228-010-2
Beilstein/REAXYS Number:
3678999
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


form

liquid

refractive index

n20/D 1.487 (lit.)

bp

155 °C/0.01 mmHg (lit.)

mp

21 °C (lit.)

density

1.566 g/mL at 25 °C (lit.)

SMILES string

CCO[Ta](OCC)(OCC)(OCC)OCC

InChI

1S/5C2H5O.Ta/c5*1-2-3;/h5*2H2,1H3;/q5*-1;+5

InChI key

HSXKFDGTKKAEHL-UHFFFAOYSA-N

Application

Tantalum(V) ethoxide precursor is used to deposit ultra thin films of Tantalum oxide and other tantalum containing films by atomic layer deposition and chemical vapor deposition methods


Still not finding the right product?

Explore all of our products under 乙醇钽(V)


pictograms

Flame

signalword

Warning

hcodes

Hazard Classifications

Flam. Liq. 3

存储类别

3 - Flammable liquids

wgk

WGK 1

flash_point_f

84.2 °F - closed cup

flash_point_c

29 °C - closed cup

法规信息

新产品

此项目有



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



I A Elsum et al.
Oncogene, 33(48), 5523-5533 (2013-11-28)
Lung cancer is the leading cause of cancer deaths worldwide with non small-cell lung cancer (NSCLC) accounting for 80% of all lung cancers. Although activating mutations in genes of the RAS-MAPK pathway occur in up to 30% of all NSCLC
Catharina M L Zegers et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(24), 6389-6397 (2014-10-16)
Increased tumor metabolism and hypoxia are related to poor prognosis in solid tumors, including non-small cell lung cancer (NSCLC). PET imaging is a noninvasive technique that is frequently used to visualize and quantify tumor metabolism and hypoxia. The aim of
Michel van Kruchten et al.
Cancer discovery, 5(1), 72-81 (2014-11-09)
It is unknown whether the current dose of fulvestrant, an estrogen receptor (ER) antagonist, is sufficient for maximal ER downregulation in patients with metastatic breast cancer. We performed a feasibility study to assess ER availability before and during fulvestrant. Sixteen



全球贸易项目编号

货号GTIN
CDS020603-5MG04061828993871
760404-25G04061838478597